Selective serotonin-reuptake inhibitors: An update

Harvard Review of Psychiatry

Volumn 7, Issue 2, 1999, Pages 69-84

  Masand, Prakash S ^a   Gupta, Sanjay ^a,b,c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Olean General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CAFFEINE; CITALOPRAM; CLONAZEPAM; CLONIDINE; CYTOCHROME P450; DEXAMPHETAMINE; FAMOTIDINE; FLUOXETINE; FLUVOXAMINE; HETEROCYCLIC COMPOUND; IBUPROFEN; LORAZEPAM; METHYLPHENIDATE; NIZATIDINE; PAROXETINE; PYRIDOXINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TERAZOSIN; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM;

DEPRESSION; DOSE CALCULATION; DRUG CLEARANCE; DRUG MECHANISM; DYSTHYMIA; EATING DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; MENTAL DISEASE; OBSESSION; ORTHOSTATIC HYPOTENSION; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; TREATMENT INDICATION;

EID: 0032887151     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1093/hrp/7.2.69     Document Type: Review

References (185)

1. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-902.
2. Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec NL, Galin RS, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16:715-30.
3. Sclar DA, Robison LM, Skaer TL, Galin RS, Legg RF, Nemec NL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412.
4. Hale AS. The importance of accidents in evaluating the cost of SSRIs: a review. Int Clin Psychopharmacol 1994;9:195-201.
5. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, Oklahoma: Professional Communications, 1996.
6. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1994; 9(suppl 1):19-26.
7. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy, and tolerability in the treatment of depression. CNS Drugs 1997;8:410-31.
8. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;104:277-86.
9. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
10. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:94-102.
11. Hall H, Sällemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol 1984;54:379-84.
12. Guze BH, Ferng HK, Szuba MP, Richeimer S. The psychiatric drug handbook. St. Louis: Mosby-Year Book, 1992.
13. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
14. Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl 1989;350:89-90.
15. Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 1996;57(suppl 5): 12-22.
16. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl 1):1-21.
17. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32(suppl 1):22-30.
18. Masand PS, Chengappa KNR, Edwards W. Somatic treatments. In: Goldman LS, Wise TN, Brody DS, eds. Psychiatry for primary care physicians. Chicago: American Medical Association, 1998:332-64.
19. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
20. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
21. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55 (suppl):3-15.
22. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997;6:10-8.
23. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
24. Anonymous. Physicians' desk reference. Montvale, New Jersey: Medical Economics, 1998.
25. Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. J Clin Psychiatry Monogr 1995;13:2-12.
26. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995;56:52-5.
27. Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8:197-202.
28. Van Moffaert M, Bartholomé F, Cosyns P, De Nayer AR, Mertens C. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 1995;10:393-405.
29. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995;56: 229-37.
30. Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;55:85-120.
31. De Wilde J, Spiers R, Mertens C, Bartholomé F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-5.
32. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993;13(6, suppl 2):18-22S.
33. Gagiano CA. A double-blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 1993;4:145-52.
34. Montgomery SA, Djarv L. The antidepressant efficacy of citalopram. Int Clin Psychopharmacol 1996;11(suppl 1):29-33.
35. Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
36. Bougerol T, Scotto JC, Patris M, Strub N, Lemming O, Petersen HEH. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest 1997;14:77-89.
37. Ekselius L, Von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-31.
38. Pope HG Jr, McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988;145:1292-4.
39. Gupta S, Ghaly N, Dewan M. Augmenting fluoxetine with dextroamphetamine to treat refractory depression. Hosp Community Psychiatry 1992;43:281-3.
40. Crowe D, Collins JP, Rosse RB. Thyroid hormone supplementation of fluoxetine treatment [Letter]. J Clin Psychopharmacol 1990;10:150-1.
41. Gupta S, Masand P, Tanquary JF. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry 1991;159:866-7.
42. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-20.
43. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988;154:125-34.
44. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-9.
45. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-7.
46. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-43.
47. Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry 1998;59(suppl 5):65-8.
48. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiatry 1983; 140:11-20.
49. Kocsis JH, Frances AJ. A critical discussion of DSM-III dysthymic disorder. Am J Psychiatry 1987;144:1534-42.
50. Klein DN, Taylor EB, Dickstein S, Harding K. Primary early-onset dysthymia: comparison with primary nonbipolar non-chronic major depression on demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome. J Abnorm Psychol 1988;97:387-98.
51. Kocsis JH, Markowitz JC, Prien RF. Comorbidity of dysthymic disorder. In: Maser JD, Cloninger CR, eds. Comorbidity of mood and anxiety disorders. Washington, DC: American Psychiatric Press, 1990:317-28.
52. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993;150:1169-75.
53. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777-84.
54. Lapierre YD. Pharmacological therapy of dysthymia. Acta Psychiatr Scand Suppl 1994;383:42-8.
55. Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, Georges MS, Callahan A, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl 1996;11:153-80.
56. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4: 313-22.
57. Simpson SG, DePaulo JR. Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991;11:52-4.
58. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-50.
59. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
60. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104.
61. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
62. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
63. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesaña-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997;38:246-52.
64. Masand P, Murray GB, Pickett P. Psychostimulants in poststroke depression. J Neuropsychiatry Clin Neurosci 1991;3: 23-7.
65. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996;37:57-62.
66. Pickett P, Masand P, Murray GB. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J Geriatr Psychiatry Neurol 1990;3:146-51.
67. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996;19:515-47.
68. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994;55(suppl A):83-7.
69. Cunningham LA. Depression in the medically ill: choosing an antidepressant. J Clin Psychiatry 1994;55(suppl A):90-7.
70. Rosenbaum JF, Pollack MH, Pollock RA. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry 1996;57(suppl 10):44-8.
71. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologica 1964;5:397-408.
72. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-9.
73. Westenberg HG. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J Affect Disord 1996;40:85-93.
74. Den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74.
75. Westenberg HGM, Den Boer JA. Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacol Bull 1989;25:119-23.
76. Den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double blind, placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102: 85-94.
77. Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, et al. A double-blind, placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32:135-41.
78. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
79. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13: 321-6.
80. Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, et al. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anx Disord 1996;10: 219-42.
81. LeCrubier Y. A double blind, placebo-controlled study of paroxetine and clomipramine in the treatment of panic disorder. Presented at the Seventh Congress of the European College of Neuropsychopharmacology, Copenhagen, Denmark, November 1994.
82. Burnham DB, Steiner MX, Gergel IP, Lydiard RB. Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double blind study. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1995.
83. Dunbar G, Judge R. A double blind placebo-controlled study of paroxetine and clomipramine in the treatment of panic disorder. Presented at the Eighth Congress of the European College of Neuropsychopharmacology, Venice, Italy, September/October 1995.
84. Dunbar G, Judge R, Morton N. Long-term evaluation of paroxetine, clomipramine, and placebo in the treatment of panic disorder. Presented at the Eighth Congress of the European College of Neuropsychopharmacology, Venice, Italy, September/October 1995.
85. Steiner M, Oakes R, Gergel IP, Burnham DB, Wheadon DE. A fixed-dose study of paroxetine and placebo in the treatment of panic disorder. Presented at the Eighth Congress of the European College of Neuropsychopharmacology, Venice, Italy, September/October 1995.
86. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-9.
87. Steiner M, Oakes R, Gergel IP, Burnham DB, Wheadon DE. A fixed-dose study of paroxetine and placebo in the treatment of panic disorder. Presented at the 148th Annual Meeting of the American Psychiatric Association, Miami, Florida, May 1995.
88. Du Boff E, England D, Ferguson JM, Londberg PD, Rosenthal MN, Smith W, et al. Sertraline in the treatment of panic disorder. Presented at the Eighth Congress of the European College of Neuropsychopharmacology, Venice, Italy, September/October 1995.
89. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996;57(suppl 10):51-8.
90. Gorman J, Wolkow R. Sertraline as a treatment for panic disorder [Abstract]. Neuropsychopharmacology 1994;10 (suppl, pt2):197S.
91. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-32.
92. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-21.
93. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-8.
94. Wade AG. The optimal therapeutic area for SSRIs: panic disorder. Presented at the Eighth Congress of the European College of Neuropsychopharmacology, Venice, Italy, September/ October 1995.
95. Lepola U, Leinonen E, Koponen H. Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry 1996;29:30-2.
96. Karno M, Golding JM, Sorenson SB, Burnham MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094-9.
97. Kelly A. Selecting a serotonin reuptake inhibitor for obsessive compulsive disorder. Prim Psychiatry 1997;4:61-70.
98. Black A, ed. The natural history of obsessional neurosis. London, England: Methuen, 1974.
99. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174-88.
100. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-51.
101. Bastani B, Nash JF, Meltzer HY. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:833-9.
102. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 1992; 53(suppl):29-37.
103. Smeraldi E, Erzegovesi S, Bianchi I, Pasquali L, Cocchi S, Ronchi P. Fluvoxamine vs clomipramine in the treatment of obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry 1992;8:63-5.
104. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-5.
105. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry 1990; 47:926-32.
106. Ananth J, Elmishad A, Wohl M. Clomipramine vs fluoxetine in obsessive compulsive disorder: an uncontrolled study. Adv Ther 1993;10:288-92.
107. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993;3: 143-52.
108. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
109. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, et al. Results of a double-blind, placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26:279-84.
110. Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1990;147:923-8.
111. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. A 1-year, double-blind, placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10: 57-65.
112. Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 1997;58(suppl 12):18-22.
113. Kaye NS, Dancu C. Paroxetine and obsessive-compulsive disorder [Letter]. Am J Psychiatry 1994;151:1523.
114. Goodman WK, Steiner M, Bushnell W, Hollander E. Efficacy of fixed doses of paroxetine in the treatment of obsessive compulsive disorder: a randomized double blind trial. J Clin Psychopharmacol [In press].
115. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997;17:267-71.
116. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 1997;7: 157-66.
117. Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997;96:343-6.
118. Stein DJ, Simeon D, Cohen LJ, Hollander E. Trichotillomania and obsessive-compulsive disorder. J Clin Psychiatry 1995;56(suppl 4):28-34.
119. Koran LM, Ringold A, Hewlett W. Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull 1992; 28:145-9.
120. Winchel RM, Jones JS, Stanley B, Molcho A, Stanley M. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 1992;53:304-8.
121. Christenson GA, Mackenzie TB, Mitchell JE, Callies AL. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 1991;148:1566-71.
122. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-47.
123. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8.
124. Crisp AH, Lacey JH, Crutchfield M. Clomipramine and 'drive' in people with anorexia nervosa: an in-patient study. Br J Psychiatry 1987;150:355-8.
125. Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry 1990;51:378-82.
126. Gergel I, Pitts C, Oakes R, Kumar R. Significant improvement in Symptoms of social phobia after paroxetine treatment [Abstract]. Biol Psychiatry 1997;42(suppl):26S.
127. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Coté D, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16:218-22.
128. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-71.
129. Van Vliet IM, Den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115:128-34.
130. Keck PE Jr, McElroy SL. New uses for antidepressants: social phobia. J Clin Psychiatry 1997;58(suppl 14):32-6.
131. Lydiard RB, Falsetti SA. Treatment options for social phobia. Psychiatr Ann 1995;25:570-6.
132. Yonkers KA, Brown WA. Pharmacologic treatments for premenstrual dysphoric disorder. Psychiatr Ann 1996;26:586-9.
133. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991;52:290-3.
134. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992;80:339-44.
135. Menkes DB, Taghavi E, Mason PA, Spears GF, Howard RC. Fluoxetine treatment of severe premenstrual syndrome. BMJ 1992;305:346-7.
136. Brandenburg S, Tuynman-Qua H, Verheij R, Pepplinkhuizen L. Treatment of premenstrual syndrome with fluoxetine: an open study. Int Clin Psychopharmacol 1993;8:315-7.
137. Pearlstein TB, Stone AB. Long-term fluoxetine treatment in late luteal phase dysphoric disorder. J Clin Psychiatry 1994; 55:332-5.
138. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995;332:1529-34.
139. Yonkers KA, Halbreich U, Freeman E, Brown C, Pearlstein T Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull 1996;32:41-6.
140. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12:167-76.
141. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol 1996;16:3-8.
142. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18:390-8.
143. Veeninga AT, Westenberg HGM, Weusten JTN. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology 1990;102:414-6.
144. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:791-5.
145. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, et al. Double-blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992;31:1062-9.
146. Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol 1993;16:167-72.
147. Como PG, Kurlan R. An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome. Neurology 1991;41:872-4.
148. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1990;29:45-8.
149. Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-45.
150. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression [Letter]. J Am Acad Child Adolesc Psychiatry 1991;30:508-9.
151. Todd RD. Fluoxetine in autism [Letter]. Am J Psychiatry 1991;148:1089.
152. Mehlinger R, Scheftner WA, Poznanski E. Fluoxetine and autism [Letter]. J Am Acad Child Adolesc Psychiatry 1990;29: 985.
153. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991;30:762-7.
154. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993;3:1-10.
155. Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994;33:993-9.
156. Black B, Uhde TW Elective mutism as a variant of social phobia. J Am Acad Child Adolesc Psychiatry 1992;31:1090-4.
157. Kaye WH, Weltzin TE, Hsu LKG, Bulik CM. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry 1991;52:464-71.
158. Lyles B, Sarkis E, Kemph JP Fluoxetine and anorexia [Letter]. J Am Acad Child Adolesc Psychiatry 1990;29:984-5.
159. Iancu I, Ratzoni G, Weitzman A, Apter A. More fluoxetine experience [Letter]. J Am Acad Child Adolesc Psychiatry 1992;31:755-6.
160. Trygstad O. Drugs in the treatment of bulimia nervosa. Acta Psychiatr Scand Suppl 1990;361:34-7.
161. Wilcox JA. Fluoxetine and bulimia. J Psychoactive Drugs 1990;22:81-2.
162. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993;94(suppl 5A): 2-12S.
163. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-45.
164. Menting JE, Honig A, Verhey FR, Hartmans M, Rozendaal N, De Vet HC, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 1996;11:165-75.
165. Gutierrez MM, Abramowitz W. Citalopram pharmacokinetics: a comparison between young and elderly subjects. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology, Kamuela, Hawaii, December 1997.
166. Miller LJ. Psychiatric medication during pregnancy: understanding and minimizing risks. Psychiatr Ann 1994;24: 69-75.
167. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269: 2246-8.
168. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
169. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-20.
170. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336: 258-62.
171. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279: 609-10.
172. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-50.
173. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992;89:676-7.
174. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997;154: 1255-60.
175. Mammen OK, Perel JM, Rudolph G, Foglia JP, Wheeler SB. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997;58:100-3.
176. Jensen PN, Olesen OV, Bertelsen A, Linnet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997;19: 236-9.
177. Seagraves RT. Overview of sexual dysfunction complicating the treatment of depression: effects of psychotropic drugs on human erection and ejaculation. J Clin Psychiatry Monogr 1992;10:4-10.
178. Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993;54:209-12.
179. Patterson WM. Fluoxe tine-induced sexual dysfunction [Letter]. J Clin Psychiatry 1993;54:71.
180. Ellison JM. Antidepressant-induced sexual dysfunction: review, classification, and suggestions for treatment. Harvard Rev Psychiatry 1998;6:177-89.
181. Stokes PE, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997;19:1135-250.
182. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50:339-42.
183. Settle EC Jr, Settle GP. A case of mania associated with fluoxetine. Am J Psychiatry 1984;141:280-1.
184. Gunzberger DW, Martinez D. Adverse vascular effects associated with fluoxetine [Letter]. Am J Psychiatry 1992;149: 1751.
185. Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA. Fluoxetine as a cause of SIADH [Letter]. Am J Psychiatry 1991;148:542-3.